296 related articles for article (PubMed ID: 25059314)
21. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Chavez AH; Scott Coffield K; Hasan Rajab M; Jo C
Asian J Androl; 2013 Mar; 15(2):246-8. PubMed ID: 23353723
[TBL] [Abstract][Full Text] [Related]
22. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer.
Plym A; Folkvaljon Y; Garmo H; Holmberg L; Johansson E; Fransson P; Stattin P; Lambe M
J Sex Med; 2014 Aug; 11(8):2100-8. PubMed ID: 24862360
[TBL] [Abstract][Full Text] [Related]
23. Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database.
Chappidi MR; Kates M; Sopko NA; Joice GA; Tosoian JJ; Pierorazio PM; Bivalacqua TJ
J Sex Med; 2017 Jun; 14(6):810-817. PubMed ID: 28460994
[TBL] [Abstract][Full Text] [Related]
24. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events.
Belladelli F; Li S; Zhang CA; Muncey W; Del Giudice F; Glover F; Seranio N; Basran S; Fallara G; Montorsi F; Salonia A; Eisenberg ML
J Sex Med; 2023 Nov; 20(12):1399-1406. PubMed ID: 37861186
[TBL] [Abstract][Full Text] [Related]
25. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
26. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
[TBL] [Abstract][Full Text] [Related]
27. Baseline prevalence of erectile dysfunction in a prostate cancer screening population.
Walz J; Perrotte P; Suardi N; Hutterer G; Jeldres C; Bénard F; Valiquette L; Graefen M; Montorsi F; Karakiewicz PI
J Sex Med; 2008 Feb; 5(2):428-35. PubMed ID: 18086160
[TBL] [Abstract][Full Text] [Related]
28. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Giuliano F; Oelke M; Jungwirth A; Hatzimouratidis K; Watts S; Cox D; Viktrup L
J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
[TBL] [Abstract][Full Text] [Related]
29. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study.
Oreggia D; Ventimiglia E; Capogrosso P; Boeri L; Cazzaniga W; Pederzoli F; Chierigo F; Dehò F; Montorsi F; Salonia A
PLoS One; 2018; 13(8):e0201601. PubMed ID: 30096166
[TBL] [Abstract][Full Text] [Related]
30. Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study.
Skeldon SC; Cheng L; Morgan SG; Detsky AS; Goldenberg SL; Law MR
J Sex Med; 2017 Dec; 14(12):1597-1605. PubMed ID: 29198514
[TBL] [Abstract][Full Text] [Related]
31. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
Stridh A; Pontén M; Arver S; Kirsch I; Abé C; Jensen KB
JAMA Netw Open; 2020 Mar; 3(3):e201423. PubMed ID: 32196105
[TBL] [Abstract][Full Text] [Related]
32. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study.
Kirby MG; Schnetzler G; Zou KH; Symonds T
Int J Clin Pract; 2011 Jul; 65(7):797-806. PubMed ID: 21676121
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Baseline Erectile Dysfunction (ED) in an Australian Cohort of Men with Localized Prostate Cancer.
Ong WL; McLachlan H; Millar JL
J Sex Med; 2015 May; 12(5):1267-74. PubMed ID: 25847707
[TBL] [Abstract][Full Text] [Related]
35. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
[TBL] [Abstract][Full Text] [Related]
36. Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis.
Duun-Henriksen AK; Dehlendorff C; Røder MA; Skriver C; Pottegård A; Friis S; Brasso K; Larsen SB
Acta Oncol; 2022 Aug; 61(8):931-938. PubMed ID: 35666094
[TBL] [Abstract][Full Text] [Related]
37. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer.
Prasad MM; Prasad SM; Hevelone ND; Gu X; Weinberg AC; Lipsitz SR; Palapattu GS; Hu JC
J Sex Med; 2010 Mar; 7(3):1062-73. PubMed ID: 20059662
[TBL] [Abstract][Full Text] [Related]
38. Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities.
Hatzichristou D; d'Anzeo G; Porst H; Buvat J; Henneges C; Rossi A; Hamidi K; Büttner H
BMC Urol; 2015 Nov; 15():111. PubMed ID: 26563171
[TBL] [Abstract][Full Text] [Related]
39. Association Between Erectile Dysfunction and Subsequent Prostate Cancer Development: A Population-Based Cohort Study With Double Concurrent Comparison Groups.
Kok VC; Hsiao YH; Horng JT; Wang KL
Am J Mens Health; 2018 Sep; 12(5):1492-1502. PubMed ID: 29708021
[TBL] [Abstract][Full Text] [Related]
40. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
